Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 29, 2025
Syndax Announces Participation in June Investor Conferences
GlobeNewswire
·
May 29, 2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as …
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 29, 2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming …
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
GlobeNewswire
·
May 29, 2025
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the …
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune …
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
GlobeNewswire
·
May 29, 2025
REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay …
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
GlobeNewswire
·
May 29, 2025
BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provided a business update. Brepocitinib program …
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
GlobeNewswire
·
May 29, 2025
NEWTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the first patient has been …
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its management team will host a company event …
Tilray Brands to Present at TD Cowen’s 9th Annual Future of the Consumer Conference
GlobeNewswire
·
May 29, 2025
NEW YORK and LEAMINGTON, Ontario, May 29, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (NASDAQ: TLRY and TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today …
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
GlobeNewswire
·
May 29, 2025
Immunovant’s new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves’ disease (GD) and a potentially registrational study in Sjögren’s disease …
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
POMPANO BEACH, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that …
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
GlobeNewswire
·
May 29, 2025
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: …
A Destructive Form of Cell Death Might Be The Key To Slowing The Human Aging Process
GlobeNewswire
·
May 29, 2025
CAMBRIDGE, United Kingdom, May 29, 2025 (GLOBE NEWSWIRE) -- LinkGevity, an AI-driven drug discovery company focused on revolutionising the treatment of aging and age-related diseases, today announces its contribution to the publication of a paper in …
La Croix-Rouge canadienne vient en aide aux personnes touchées par les feux de forêt au Manitoba
GlobeNewswire
·
May 29, 2025
OTTAWA, Ontario, 29 mai 2025 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne collabore présentement avec les autorités dirigeantes des communautés autochtones et tous les paliers du gouvernement pour offrir des services d’inscription, d’accueil et d’ …
Canadian Red Cross supporting people impacted by Manitoba wildfires
GlobeNewswire
·
May 29, 2025
OTTAWA, Ontario, May 29, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross is currently working alongside Indigenous community leadership and all levels of government to provide registration, reception and information, emergency accommodations, meals, and …
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
·
May 29, 2025
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the …